New strategies in Barrett's esophagus: Integrating clonal evolutionary theory with clinical management

Clinical Cancer Research

Volumn 17, Issue 11, 2011, Pages 3512-3519

  Reid, Brian J ^a   Kostadinov, Rumen ^b   Maley, Carlo C ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; CANCER MORTALITY; CHEMOPROPHYLAXIS; CHROMOSOMAL INSTABILITY; CLONE; DRUG MEGADOSE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMIC INSTABILITY; GENOTYPE; HELICOBACTER INFECTION; HETEROZYGOSITY LOSS; HUMAN; INTESTINE METAPLASIA; LOW DRUG DOSE; MUCOSAL IMMUNITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STATISTICAL ANALYSIS;

ADENOCARCINOMA; BARRETT ESOPHAGUS; EPITHELIUM; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS, PEPTIC; GASTROESOPHAGEAL REFLUX; GENES, P16; GENOMIC INSTABILITY; GENOTYPE; HELICOBACTER PYLORI; HUMANS; METAPLASIA; PRECANCEROUS CONDITIONS;

EID: 79957881949     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2358     Document Type: Review

References (66)

1. Wang KK, Sampliner REPractice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97.
2. Barrett NR. Chronic peptic ulcer of the oesophagus and 'oesophagitis'. Br J Surg 1950;38:175-82.
3. Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg 1975;70:826-35.
4. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998;93:1028-32.
5. Thomas T, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis: cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 2007;26:1465-77.
6. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008;168:237-49. (Pubitemid 352019777)
7. Anderson LA, Murray LJ, Murphy SJ, Fitzpatrick DA, Johnston BT, Watson RG, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 2003;52:1081-4. (Pubitemid 36877416)
8. Solaymani-Dodaran M, Logan RF, West J, Card T. Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study. Am J Gastroenterol 2005;100:2616-21.
9. Moayyedi P, Burch N, Akhtar-Danesh N, Enaganti SK, Harrison R, Talley NJ, et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2008;27:316-20.
10. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40. (Pubitemid 19105891)
11. Fleming TR, Prentice RL, Pepe MS, Glidden D. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med 1994;13:955-68. (Pubitemid 24141115)
12. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010;10:87-101.
13. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40. (Pubitemid 34173814)
14. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56. (Pubitemid 36055338)
15. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 2009;100:551-7.
16. Overholt BF, Lightdale CJ, Wang KK, Canto MI, Burdick S, Haggitt RC, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-98. (Pubitemid 41383764)
17. Overholt BF, Wang KK, Burdick JS, Lightdale CJ, Kimmey M, Nava HR, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007;66:460-8. (Pubitemid 47304412)
18. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277-88.
19. Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK. History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology 2010;138:854-69.
20. Romero Y, Cameron AJ, Locke GR 3rd, Schaid DJ, Slezak JM, Branch CD, et al. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 1997;113:1449-56. (Pubitemid 27461230)
21. Groves C, Jankowski J, Barker F, Holdstock G. A family history of Barrett's oesophagus: another risk factor? Scand J Gastroenterol 2005;40:1127-8.
22. Chak A, Ochs-Balcom H, Falk G, Grady WM, Kinnard M, Willis JE, et al. Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 2006;15:1668-73. (Pubitemid 44497103)
23. Munitiz V, Parrilla P, Ortiz A, Martinez-de-Haro LF, Yelamos J, Molina J. High risk of malignancy in familial Barrett's esophagus: presentation of one family. J Clin Gastroenterol 2008;42:806-9.
24. Cameron AJ, Lagergren J, Henriksson C, Nyren O, Locke GR 3rd, Pedersen NL. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002;122:55-9. (Pubitemid 34049194)
25. Mohammed I, Cherkas LF, Riley SA, Spector TD, Trudgill NJ. Genetic influences in gastro-oesophageal reflux disease: a twin study. Gut 2003;52:1085-9. (Pubitemid 36877417)
26. Gelfand MD. Barrett esophagus in sexagenarian identical twins. J Clin Gastroenterol 1983;5:251-3. (Pubitemid 13097030)
27. Chak A, Faulx A, Kinnard M, Brock W, Willis J, Wiesner GL, et al. Identification of Barrett's esophagus in relatives by endoscopic screening. Am J Gastroenterol 2004;99:2107-14. (Pubitemid 39524698)
28. Ochs-Balcom HM, Falk G, Grady WM, Kinnard M, Willis J, Elston R, et al. Consortium approach to identifying genes for Barrett's esophagus and esophageal adenocarcinoma. Transl Res 2007;150:3-17. (Pubitemid 46950945)
29. Roach J, Glusman G, Smit AFA, Huff CD, Hubley R, Shannon PT, et al. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 2010;328:636-9.
30. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
31. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899-905.
32. van Baal JW, Milana F, Rygiel AM, Sondermeijer CM, Spek CA, Bergman JJ, et al. A comparative analysis by SAGE of gene expression profiles of esophageal adenocarcinoma and esophageal squamous cell carcinoma. Cell Oncol 2008;30:63-75. (Pubitemid 351161034)
33. Peng D, Sheta EA, Powell SM, Moskaluk CA, Washington K, Goldknopf IL, et al. Alterations in Barrett's-related adenocarcinomas: a proteomic approach. Int J Cancer 2008;122:1303-10. (Pubitemid 351287230)
34. Zhao J, Chang AC, Li C, Shedden KA, Thomas DG, Misek DE, et al. Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping. Mol Cell Proteomics 2007;6:987-99. (Pubitemid 47019400)
35. Li X, Galipeau PC, Sanchez CA, Blount PL, Maley CC, Arnaudo J, et al. Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res (Phila) 2008;1:413-23.
36. Paulson TG, Maley CC, Li X, Li H, Sanchez CA, Chao DL, et al. Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 2009;15:3305-14.
37. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9. (Pubitemid 29214816)
38. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 2004;64:3414-27. (Pubitemid 38657913)
39. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Blount PL, et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 2004;64:7629-33. (Pubitemid 39372110)
40. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38:468-73.
41. Merlo LM, Shah NA, Li X, Blount PL, Vaughan TL, Reid BJ, et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) 2010;3:1388-97.
42. Leedham SJ, Preston SL, McDonald SA, Elia G, Bhandari P, Poller D, et al. Individual crypt genetic heterogeneity and the origin of meta-plastic glandular epithelium in human Barrett's oesophagus. Gut 2008;57:1041-8.
43. Orlando RC. Mucosal defense in Barrett's esophagus. In: Sharma P, Sampliner R, editors. Barrett's esophagus and esophageal adenocarcinoma. 2nd ed. Oxford, UK: Blackwell Publishing, Ltd; 2006. p. 60-72.
44. Ostrowski J, Mikula M, Karczmarski J, Rubel T, Wyrwicz LS, Bragoszewski P, et al. Molecular defense mechanisms of Barrett's meta-plasia estimated by an integrative genomics. J Mol Med 2007;85:733-43. (Pubitemid 47063526)
45. Levine DS, Rubin CE, Reid BJ, Haggitt RC. Specialized metaplastic columnar epithelium in Barrett's esophagus. A comparative transmission electron microscopic study. Lab Invest 1989;60:418-32.
46. Levine DS, Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium. Gastroenterology 1989;96:355-67. (Pubitemid 19045266)
47. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 2007;4:e67.
48. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005;6:945-52. (Pubitemid 41685227)
49. Pepper JW, Findlay CS, Kassen R, Spencer SL, Maley CC. Cancer research meets evolutionary biology. Evol Appl 2009;2:62-70.
50. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17:510-22.
51. Jankowski J, Sharma P. Review article: approaches to Barrett's oesophagus treatment-the role of proton pump inhibitors and other interventions. Aliment Pharmacol Ther 2004;19[Suppl 1]:54-9. (Pubitemid 38253493)
52. Jankowski J, Barr H. Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. BMJ 2006;332:1512. (Pubitemid 44365302)
53. Blaser MJ. Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prev Res (Phila) 2008;1:308-11.
54. Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 2009;137:588-97.
55. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci 2002;27:339-44.
56. Jenkins GJ, Cronin J, Alhamdani A, Rawat N, D'Souza F, Thomas T, et al. The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-kappaB activation in oesophageal cells, with a mechanism of action involving ROS. Mutagenesis 2008;23:399-405.
57. Grisham MB, Jourd'heuil D, Wink DA. Review article: chronic inflammation and reactive oxygen and nitrogen metabolism-implications in DNA damage and mutagenesis. Aliment Pharmacol Ther 2000;14 [Suppl 1]:3-9.
58. Sihvo EI, Salminen JT, Rantanen TK, Rämö OJ, Ahotupa M, Färkkilä M, et al. Oxidative stress has a role in malignant transformation in Barrett's oesophagus. Int J Cancer 2002;102:551-5. (Pubitemid 35334460)
59. Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines - energy regulation from the human perspective. J Nutr 2006;136[Suppl]:1935S-9S.
60. Turker MS, Gage BM, Rose JA, Elroy D, Ponomareva ON, Stambrook PJ, et al. A novel signature mutation for oxidative damage resembles a mutational pattern found commonly in human cancers. Cancer Res 1999;59:1837-9. (Pubitemid 29186153)
61. Tobey NA, Argote CM, Vanegas XC, Barlow W, Orlando RC. Electrical parameters and ion species for active transport in human esophageal stratified squamous epithelium and Barrett's specialized columnar epithelium.AmJ Physiol Gastrointest Liver Physiol 2007;293:G264-70.
62. Cairns J. Mutation selection and the natural history of cancer. Nature 1975;255:197-200.
63. Dixon J, Strugala V, Griffin SM, Welfare MR, Dettmar PW, Allen A, et al. Esophageal mucin: an adherent mucus gel barrier is absent in the normal esophagus but present in columnar-lined Barrett's esophagus. Am J Gastroenterol 2001;96:2575-83.
64. Glickman JN, Blount PL, Sanchez CA, Cowan DS, Wongsurawat VJ, Reid BJ, et al. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus. Hum Pathol 2006;37:1304-15. (Pubitemid 44380275)
65. Lao-Sirieix P, Corovic A, Jankowski J, Lowe A, Triadafilopoulos G, Fitzgerald RC. Physiological and molecular analysis of acid loading mechanisms in squamous and columnar-lined esophagus. Dis Esophagus 2008;21:529-38.
66. Jovov B, Van Itallie CM, Shaheen NJ, Carson JL, Gambling TM, Anderson JM, et al. Claudin-18: a dominant tight junction protein in Barrett's esophagus and likely contributor to its acid resistance. Am J Physiol Gastrointest Liver Physiol 2007;293:G1106-13.